Zabbio, Inc.

Del Mar, CA

UEI
NK7AM6NNHQD1
CAGE
86Q96
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
147 13th St, Del Mar, CA 92014, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Grant subawards

Prime recipient Prime award Amount Awarded
Trustees Of Boston University Project One - ZabBio, Inc. Scope of Work ZabBio will work as a member of a contraceptive development team headed by investigators at Boston University Medical… P50HD096957 $1,881,665

Similar vendors

Vendor Location Primary NAICS
Panorama Research Incorporated UEI LYVHC3ARFRJ7 Sunnyvale, CA —
Tega Therapeutics Inc. UEI C1LJLCS3PM51 San Diego, CA 622110 General Medical and Surgical Hospitals
Invvax, Inc. UEI XD11NMF7NB14 Cypress, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Research And Development UEI KTUYMKC7J4P5 San Diego, CA —
Epigen Biosciences Inc. UEI L1EDVCGK2327 San Diego, CA 325199 All Other Basic Organic Chemical Manufacturing

About the company

Zabbio Inc. is a corporate, for-profit organization registered in SAM.gov, located in San Diego, California, with a focus on biotechnology and medical research development. The company appears to specialize in advanced medical therapeutic research, particularly in areas involving monoclonal antibodies and innovative pharmaceutical product development. While specific details about the company's full organizational background are limited in the provided documentation, the firm demonstrates significant expertise in developing complex medical interventions and collaborating with academic research institutions.

Zabbio Inc. has been awarded federal grants primarily in the biomedical research domain, with notable work in infectious disease and contraceptive technologies. The company's most recent significant federal grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), involves developing a monoclonal antibody therapy for treating neonatal herpes simplex virus infections, representing a sophisticated medical research project. Additionally, Zabbio has been involved in sub-grant work with prominent research institutions, including Boston University and Emory University, focusing on contraceptive development projects. These sub-grants have involved critical research activities such as overseeing drug substance manufacturing, conducting nonclinical studies, managing clinical trials, and handling regulatory interactions with the FDA. The company's grant work demonstrates a strong capability in pharmaceutical research, product development, and regulatory compliance across multiple complex medical research domains.

Quick answers

Is Zabbio, Inc. registered in SAM.gov?

Yes. Zabbio, Inc.'s SAM.gov registration is active through January 12, 2027.

What is Zabbio, Inc.'s CAGE code?

Zabbio, Inc.'s CAGE code is 86Q96, and its Unique Entity ID (UEI) is NK7AM6NNHQD1.

What is Zabbio, Inc.'s most recent federal award?

Zabbio, Inc.'s most recent federal grant award is Development of a monoclonal therapy for neonatal herpes (R44AI191836), from National Institute of Allergy and Infectious Diseases (NIH), on August 8, 2025.

On GovTribe

See Zabbio, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe